| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| deletion
|
|
| |
in malignant melanoma, renal cell carcinoma, cervical precancer, breast cancer lung cancer, gastrointestinal tumor, Merkel cell carcinoma nasopharyngeal carcinoma, head and neck cancer | | tumoral
|
| LOH
|
|
| |
in nasopharyngeal carcinoma, esophageal cancer, renal cell carcinoma, lung cancer, bronchial cancer, esophageal squamous cell carcinoma, | | tumoral
|
| LOH
|
|
| |
in pancreatic islet cell tumors, head and neck cancer, cervix tumor, non small cell lung carcinoma, primary brain tumor, adenocarcinoma | | tumoral
|
| translocation
|
|
| |
in renal carcinoma | | tumoral
| somatic mutation
|
|
|
| |
in prostate cancer, uterine endometrium | | tumoral
|
|
|
| loss of function
| |
in lung and breast cancer and preinvasive bronchial lesion | | tumoral
|
|
| --low
|
| |
in renal cell carcinoma, gastric carcinoma | | tumoral
|
|
| --low
|
| |
downregulated by promoter hypermethylation and histone hypoacetylation in epithelial ovarian cancer | | tumoral
|
|
| --low
|
|
or silenced in most colorectal and gastric cell lines due to promoter methylation, whereas broadly expressed in normal tissues including colon and stomach, and unmethylated in expressing cell lines and immortalised normal colon epithelial cells  | | tumoral
|
|
| --low
|
| |
by promoter hypermethylation and histone deacetylation may be important in nasopharyngeal carcinoma tumorigenesis | | tumoral
|
|
| --low
|
| |
by promoter methylation, associated with poor prognosis in non-small cell lung carcinoma | |
